Stefan Ibach

402 total citations
10 papers, 154 citations indexed

About

Stefan Ibach is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Stefan Ibach has authored 10 papers receiving a total of 154 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Stefan Ibach's work include Chronic Lymphocytic Leukemia Research (5 papers), Gastric Cancer Management and Outcomes (3 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). Stefan Ibach is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Gastric Cancer Management and Outcomes (3 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). Stefan Ibach collaborates with scholars based in Germany, France and United Kingdom. Stefan Ibach's co-authors include Jörg Trojan, S Daum, Dirk Behringer, Michael Schenk, Salah‐Eddin Al‐Batran, Frank Kullmann, Florian Lordick, Volker Kunzmann, Horst Lindhofer and Maren Knödler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Stefan Ibach

8 papers receiving 149 citations

Peers

Countries citing papers authored by Stefan Ibach

Since Specialization

Citations

This map shows the geographic impact of Stefan Ibach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Ibach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Ibach more than expected).

Fields of papers citing papers by Stefan Ibach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Ibach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Ibach. The network helps show where Stefan Ibach may publish in the future.

Co-authorship network of co-authors of Stefan Ibach

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Ibach. A scholar is included among the top collaborators of Stefan Ibach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Ibach. Stefan Ibach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer 2024 ·JCO Clinical Cancer Informatics ·Marinde J. G. Bond, Maarten van Smeden, Koen Degeling, Chiara Cremolini, Hans‐Joachim Schmoll, Carlotta Antoniotti, Sara Lonardi, Sabina Murgioni, Daniele Rossini, Stefan Ibach, Miriam Koopman, Rutger‐Jan Swijnenburg, Cornelis J.A. Punt, Anne M. May, Johannes J.M. Kwakman	2
2	Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma 2024 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Regina Herbst, Annette Hänel, Anke Morgner, Stefan Ibach, Stephan Fricke, Mathias Hänel	0
3	Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer – Data From a Randomized German Phase II Trial 2022 ·Ultraschall in der Medizin - European Journal of Ultrasound ·Visvakanth Sivanathan, (unknown), Thomas Thomaidis, (unknown), M. Stahl, Florian Lordick, Stefan Ibach, Stephan Kanzler, Andreas Adler, Stefan Mönig, Carl Christoph Schimanski, A Ignee, Christoph F. Dietrich, Peter R. Galle, Markus Moehler	2
4	Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer 2018 ·British Journal of Cancer ·Maren Knödler, (unknown), Volker Kunzmann, Jörg Trojan, S Daum, Michael Schenk, Frank Kullmann, (unknown), Dirk Behringer, Michael Stahl, Salah‐Eddin Al‐Batran, Ulrich Hacker, Stefan Ibach, Horst Lindhofer, Florian Lordick	66
5	Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial. 2018 ·Journal of Clinical Oncology ·Florian Lordick, Volker Kunzmann, Jörg Trojan, S Daum, Michael Schenk, Frank Kullmann, (unknown), Dirk Behringer, M. Stahl, Salah‐Eddin Al‐Batran, Stefan Ibach, (unknown), (unknown)	5
6	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome 2017 ·Leukemia & lymphoma ·(unknown), Billy Michael Chelliah Jebaraj, Christof Schneider, Jennifer Edelmann, Florence Cymbalista, Véronique Leblond, Alain Delmer, Stefan Ibach, Eugen Tausch, Annika Scheffold, Johannes Bloehdorn, Michael Hallek, Peter Dreger, Hartmut Döhner, Stephan Stilgenbauer	13
7	High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial 2014 ·Blood ·Jennifer Edelmann, (unknown), Stefan Ibach, Karlheinz Holzmann, Eugen Tausch, Johannes Bloehdorn, Daniel Mertens, Thorsten Zenz, Florence Cymbalista, Véronique Leblond, Alain Delmer, John G. Gribben, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer	0
8	Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia 2013 ·Annals of Hematology ·N. Niederle, (unknown), Leopold Balleisen, W. Heit, Wolfgang Knauf, (unknown), Werner Freier, Axel Hinke, Stefan Ibach, Hartmut Eimermacher	30
9	Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial 2013 ·Blood ·Carmen D. Schweighofer, Florence Cymbalista, Carolin Müller, Raymonde Busch, Raphaël Porcher, Petra Langerbeins, Bruno Cazin, Anna‐Maria Fink, Brigitte Dreyfus, Stefan Ibach, Stéphane Leprêtre, Kirsten Fischer, Ursula Vehling‐Kaiser, Barbara Eichhorst, Manuela A. Bergmann, Stephan Stilgenbauer, Hartmut Döhner, Véronique Leblond, Michael Hallek, Vincent Lévy	30
10	Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia 2002 ·Hermann Schulz, Saskia K. Klein, U. Rehwald, Maximilian F. Reiser, Stefan Ibach, W. E. Aulitzky, M. Hensel, Michael Herold, D. Huhn, (unknown), Michael Hallek, (unknown), Volker Diehl, Andreas Engert	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact